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Abstract
We sought to identify fibroblast growth factor receptor 2 (FGFR2) kinase domain mutations that confer resistance
to the pan-FGFR inhibitor, dovitinib, and explore the mechanism of action of the drug-resistant mutations. We cul-
tured BaF3 cells overexpressing FGFR2 in high concentrations of dovitinib and identified 14 dovitinib-resistant
mutations, including the N550K mutation observed in 25% of FGFR2mutant endometrial cancers (ECs). Structural
and biochemical in vitro kinase analyses, together with BaF3 proliferation assays, showed that the resistance
mutations elevate the intrinsic kinase activity of FGFR2. BaF3 lines were used to assess the ability of each muta-
tion to confer cross-resistance to PD173074 and ponatinib. Unlike PD173074, ponatinib effectively inhibited all the
dovitinib-resistant FGFR2 mutants except the V565I gatekeeper mutation, suggesting ponatinib but not dovitinib
targets the active conformation of FGFR2 kinase. EC cell lines expressing wild-type FGFR2 were relatively resis-
tant to all inhibitors, whereas EC cell lines expressing mutated FGFR2 showed differential sensitivity. Within the
FGFR2mutant cell lines, three of seven showed marked resistance to PD173074 and relative resistance to dovitinib
and ponatinib. This suggests that alternative mechanisms distinct from kinase domain mutations are responsible
for intrinsic resistance in these three EC lines. Finally, overexpression of FGFR2N550K in JHUEM-2 cells (FGFR2C383R)
conferred resistance (about five-fold) to PD173074, providing independent data that FGFR2N550K can be associated
with drug resistance. Biochemical in vitro kinase analyses also show that ponatinib is more effective than dovitinib at
inhibiting FGFR2N550K. We propose that tumors harboring mutationally activated FGFRs should be treated with FGFR
inhibitors that specifically bind the active kinase.
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Introduction
Constitutive fibroblast growth factor receptor (FGFR) signaling due to
FGFR amplifications, chromosomal translocations, or gain-of-function
mutations contributes to the development and progression of multiple
cancers (reviewed in [1–3]). Tumor types associated with genetic aberra-
tions in the FGF/FGFR family include lung and breast cancer (FGFR1),
gastric cancer and endometrial cancer (EC; FGFR2), bladder cancer
and multiple myeloma (FGFR3), and rhabdomyosarcoma (FGFR4).
Preclinical in vitro and in vivo studies have indicated that FGFR kinase
inhibition in FGFR-dependent tumors is a rational approach to target
these cancers. While more selective anti-FGFR inhibitors are entering
early clinical development, the most clinically advanced inhibitors are
multi-kinase inhibitors, often developed as anti-angiogenic agents.
Dovitinib is the multi-kinase inhibitor that has shown the most prom-
ising results in multiple FGFR-dependent cancers.
Dovitinib (TKI258, previously CHIR258) is an adenosine triphos-
phate (ATP)-competitive tyrosine kinase inhibitor (TKI) with activity
against FGFR1–4, vascular endothelial growth factor receptors 1 to 3
(VEGFR1–3), PDGFRB, c-KIT, CSF1R, and FLT3 [4]. It has shown
preclinical anti-tumor activity in a range of different cancers [5–8]
including cancer models characterized by FGFR activation such
as multiple myeloma, acute myelogenous leukemia, and prostate,
bladder, and gastric cancers [4,9–14]. Dovitinib has demonstrated
anti-tumor activity in several phase I clinical trials with partial responses
and stable disease observed in several patients [15]. Dovitinib is cur-
rently in phase II clinical trials in renal cell carcinoma patients as an
anti-angiogenic agent as well as in several malignancies associated
with FGFR activation, e.g., multiple myeloma with t(4;14) translo-
cation (activated FGFR3; Clinical Trials identifier: NCT01058434)
and advanced urothelial carcinomas with and without mutations in
FGFR3 (NCT00790426). It is also in a clinical phase II study in
patients with advanced ECs expressing wild-type (WT) or mutant
FGFR2 (NCT01379534).
Despite the initial clinical effectiveness of kinase inhibitors, the long-
term efficacy of these agents is hampered by intrinsic resistance in
a subset of patients and the development of acquired resistance in a
proportion of responders. One resistance mechanism common to
many kinase inhibitors is the acquisition of secondary mutations in
the kinase domain. Mutations of the gatekeeper residue of the target
kinase are the most frequently detected drug-resistant mutation in
the clinic. Notably, mutation of the gatekeeper residue in Bcr-Abl
(T315I) is detected with high frequency in chronic myelogenous
leukemia patients with resistance against imatinib [16,17]. Likewise,
mutation of the gatekeeper residue (T790M) in the epidermal growth
factor receptor (EGFR) occurs in ∼50% of tumors with acquired
erlotinib or gefitinib resistance and represents a major obstacle for
treatment success with targeted EGFR inhibitors [18–20]. Substitu-
tions of gatekeeper residues with larger hydrophobic residues have been
shown to sterically interfere with access of drug to the hydrophobic
pocket in the ATP-binding cleft. Bcr-Abl inhibitors have also been
shown to form critical hydrogen bonds with the side chain hydroxyl
group of T315 [21]. Moreover, the gatekeeper mutations appear to
enhance tyrosine kinase activity by stabilizing a hydrophobic spine,
a network of hydrophobic interactions characteristic of activated
kinases [22]. In chronic myelogenous leukemia, the realization that
patients acquire resistance after initial response led to the develop-
ment of more potent second-generation inhibitors such as nilotinib
and dasatinib [23]; however, like imatinib, these inhibitors do
not have activity against the T315I gatekeeper mutation. This led
to the structure-based design of ponatinib (AP24534), a third-
generation inhibitor designed to have activity against WT Bcr-Abl as
well as Bcr-Abl-T315I.
Despite the importance of FGFRs as cancer drug targets, little is
known about the repertoire of mutations in FGFRs that confer resis-
tance to current FGFR inhibitors. Mutations of the gatekeeper resi-
dues in FGFR1 (V561M) and FGFR3 (V555M) have been shown
to result in in vitro resistance to the multi-kinase inhibitor PP58 and
the FGFR inhibitor AZ12908010, respectively [24], thus indicating
that mutation of the gatekeeper residue may be a general mechanism
of resistance to receptor tyrosine kinase (RTK) inhibitors.
The BaF3 screening strategy developed by von Bubnoff et al. is con-
sidered the “gold standard” method to identify drug-resistant muta-
tions in a variety of RTKs and non-receptor kinases [25,26]. In this
method, BaF3 cells are made dependent on the desired RTK, cultured
in the presence of an inhibitor against that RTK, and resistant colonies
that emerge are screened for drug-resistant mutations. This approach
has been successfully used to identify TKI-resistant mutations in
Bcr-Abl, FLT3, PDGFRA, MET, EGFR, and JAK2 [27–32] and has
effectively reproduced the pattern and relative abundance of Bcr-Abl
mutations seen clinically in imatinib-resistant patients [27]. In this study,
we used the BaF3 screening strategy to identify FGFR2 mutations that
impart resistance to dovitinib and examined the effect of these muta-
tions on FGFR2 kinase activity in vitro and in stable FGFR2-expressing
BaF3 cells. We show that the dovitinib-resistant FGFR2 mutations act
by stabilizing the active conformation of the kinase. We also examined
the ability of these dovitinib-resistant mutations to confer cross-resistance
to other FGFR inhibitors including PD173074 and ponatinib. Impor-
tantly, we discovered that ponatinib is capable of inhibiting dovitinib-
resistant gain-of-function mutations indicating that ponatinib may
be more effective as a first-line therapy as well as in the second-line set-
ting to target tumors with resistance to dovitinib. Treatment of a panel
of FGFR2 mutant EC cell lines with dovitinib and ponatinib revealed
different levels of drug sensitivity within cell lines expressing the same
FGFR2 mutation, suggesting that other intrinsic mechanisms of resis-
tance may also be present in patient tumors.
Materials and Methods
Cell Lines and Reagents
BaF3 cells were cultured as previously described [33]. The BaF3
cells used in this study were obtained directly from ATCC (Manassas,
VA) and were passaged for fewer than 6 months after their receipt, and
as such, reauthentication was not performed. The JHUEM-2,
MFE280, and MFE296 cell lines were purchased from the RIKEN
Cell Bank (Tsukuba, Japan), the DSMZ (Berlin, Germany), and the
European Collection of Cell Cultures (Salisbury, United Kingdom), re-
spectively. AN3CA, HEC1A, Ishikawa, and KLE were provided by Dr
Paul Goodfellow (Washington University, St Louis, MO). EI, EJ, and
EN1078D were provided by Dr Gordon Mills (MD Anderson Can-
cer Center, Houston, TX). Recombinant murine interleukin-3 (IL-3)
and human FGF10 were purchased from R&D Systems (Minneapolis,
MN). Dovitinib and ponatinib were purchased from Selleck Chemicals
(Houston, TX), and PD173074 was purchased from EMD Chemicals
(Gibbstown, NJ). Phospho-FGFR (P-FGFR) antibody was pur-
chased from Cell Signaling Technology (Genesearch Pty Ltd, Arundel,
Australia), total FGFR2 (T-FGFR) antibody was purchased from
Santa Cruz Biotechnology (Thermo Fisher Scientific Pty Ltd, Scoresby,
Australia), α-tubulin antibody was purchased from Sigma-Aldrich
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(Castle Hill, Australia), and IRDye 800 and IRDye 680LT secondary
antibodies were purchased from Rockland (Jomar Biosciences Pty Ltd,
Kensington, Australia).
BaF3 Screen for Dovitinib-Resistant FGFR2 Mutations
BaF3 cells were stably transduced with pEF1a.FGFR2b.IRES.neo,
pEF1a.FGFR2b.S252W.IRES.neo, or pEF1a.FGFR2b.N550K.IRES.
neo plasmid DNA using Amaxa nucleofection and selected for 14 days
in 1200 μg/ml G418, as previously reported [34]. Stably selected cells
were plated at a density of 1 × 105 and 4 × 105 cells/well in six 96-well
plates each in BaF3 growth media without IL-3, supplemented with
1 nM FGF10 and 5 μg/ml heparan sulfate. Dovitinib was added
to duplicate plates of each cell density at 5, 10, or 15× the inhibitory
concentration 50 (IC50) (100, 200, and 300 nM, respectively, for
FGFR2b- and S252W-expressing cells, and 2000, 4000, and 6000 nM,
respectively, for N550K-expressing cells). Fresh FGF10 and heparan
sulfate were added every 2 to 3 days. Colonies that grew out were
expanded in media with FGF10 and heparan sulfate, and genomic
DNA was extracted using the GenElute Mammalian Genomic DNA
MiniprepKit (Sigma-Aldrich, St Louis,MO). Inserted human FGFR2b
was amplified using overlapping primer pairs (5′-ATGCCCAGCCC-
CACATCCAG-3′ and 5′-GACTGGAAGCCGCCCATTGGTG-3′;
5′-CCCAAGGAGGCGGTCACCG-3′ and 5′-GGCATGGTCTCC-
CTGCTCAGTG-3′) and sequenced in two directions for mutations
in the intracellular domain of FGFR2b (sequencing primers available
upon request). Mutations were confirmed in an independent poly-
merase chain reaction. Amino acid substitutions are listed according
to isoform 2 of human FGFR2 (FGFR2b; NP_075259.4).
Site-directed Mutagenesis
Each putative dovitinib-resistant mutation was introduced into
full-length FGFR2b by site-directed mutagenesis (SDM), as previ-
ously described [35]. Briefly, SDM was performed on 50 ng of
pEF1a.FGFR2b.IRES.neo plasmid DNA using the QuikChange II
XL Site-Directed Mutagenesis Kit (Agilent Technologies, Santa
Clara, CA). SDM primers were designed to introduce the desired
dovitinib-resistant mutation as well as a silent mutation to introduce
a restriction site for ease in screening (primers available upon re-
quest). Plasmid DNA was isolated using the Plasmid DNA Miniprep
Kit (Qiagen, Valencia, CA), and diagnostic restriction digests were
performed. Plasmid DNA was then isolated from SDM-positive
clones using the Qiagen EndoFree Plasmid MaxiPrep Kit (Qiagen).
Mutations were confirmed by sequencing of the entire coding region
of FGFR2b (primers available upon request).
Generation of BaF3 Cells Stably Expressing
Dovitinib-Resistant FGFR2b Mutations
pEF1a.FGFR2b.IRES.neo or the various FGFR2b mutant plasmids
were introduced into BaF3 cells using the Amaxa nucleofector kit V,
according to the manufacturer’s instructions (Amaxa, Walkersville,
MD). Cells were selected in growth media containing 1200 μg/ml
G418 and 5 ng/ml IL-3 for 14 days and frozen down. Proliferation
assays in the presence or absence of drug were performed in BaF3 cells
that had not been passaged for more than 5 weeks after this initial freeze.
Generation of JHUEM-2 Cells Stably Expressing WT
and Mutant FGFR2b
JHUEM-2 cells were infected with lentiviral particles containing
pEF1α.FGFR2b.IRES.neo plasmids encoding WT FGFR2b,
FGFR2bY376C, or FGFR2bN550K. A JHUEM-2 line was also infected
with an empty pEF1α.IRES.neo vector as a control. Cells were then
selected in growth media containing 900 μg/ml G418 for 14 days
and frozen down.
IC50 Analysis
BaF3 cells expressing WT or mutant FGFR2b were plated at either
3000 or 10,000 cells per well in 96-well plates in BaF3 media without
IL-3, supplemented with 1 nM FGF10 and 5 μg/ml heparan sulfate.
Dovitinib and PD173074 were added at half-log dilutions ranging
from 10 μM to 3 nM, while ponatinib was added at half-log dilutions
ranging from 1 μM to 0.1 nM, respectively. After 72 hours, cell via-
bility was measured using the ViaLight Kit (Lonza, Walkersville, MD).
Values were normalized to DMSO vehicle control wells, and IC50
values were generated by nonlinear regression analysis with variable
slope using Prism software version 4.0c (GraphPad Software, San
Diego, CA). For the ponatinib experiments, 3000 cells per well were
seeded and assayed in triplicate on two independent days. As bio-
logic replicate data for dovitinib and PD173074 had been generated
with 10,000 cells per well, these assays were repeated a third time
with 3000 cells per well with no significant differences observed
and the presented IC50 values are the replicates of these three inde-
pendent experiments.
Parental EC cell lines and stably transfected JHUEM-2 cells were
seeded at 3000 cells per well in 96-well plates in their individual
growth media. After 24 hours, dovitinib, PD173074, and ponatinib
were added at half-log dilutions (1 nM to 10 μM). Following 72 hours
of drug treatment, cell viability was assessed using the CyQUANT Cell
Proliferation Assay Kit (Life Technologies, Carlsbad, CA). Values
were normalized to DMSO vehicle control wells, and IC50 values were
calculated as described above. Proliferation assays were performed in
triplicate on two independent days and the results were averaged.
Receptor Phosphorylation in Response to Ligand Treatment
BaF3 cells expressing WT or mutant FGFR2 were washed twice
in media minus IL-3. Cells were then resuspended in 200 μl of BaF3
media minus IL-3 containing 5 μg/ml heparan sulfate and 16 nM
FGF10 for 7.5 minutes. Cells were centrifuged at 1000 rpm for 5 min-
utes, the supernatant discarded, and the cell pellet resuspended in
200 μl of lysis buffer [1% Triton X-100, 50 mM Tris-HCl (pH 7.4),
150 mM NaCl, 2 mM Na3VO4, and 10 mM NaF]. The protein
concentration was determined using a Bio-Rad Quick Start Kit. A
total of 150 μg of protein was subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) on a 4% to 12% bis-
acrylamide gradient gel, transferred to a nitrocellulose membrane,
blocked with odyssey blocking buffer, and incubated with the primary
antibody diluted in Odyssey blocking buffer overnight at 4°C. The
membranes were washed with TBS-T and incubated with the second-
ary antibody diluted in Odyssey blocking buffer for 1 hour at room
temperature. After another washing step, the membrane was scanned
using a Lycor flatbed scanner.
Inhibition of Receptor Phosphorylation in Response to Ligand
BaF3 cells expressing WT or mutant FGFR2 were grown in T75
flasks in 50 ml of BaF3 media. Cells were washed twice with IL-3–free
media, resuspended in 35 ml of IL-3–free media, and the cells evenly
split into seven T25 flasks. An FGFR inhibitor was added to final con-
centrations of 1, 10, 30, 100, 300, 1000 nM or DMSO control corre-
sponding to the highest FGFR inhibitor concentration (0.01% vol/vol).
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Cells were incubated with the inhibitors for 90 minutes at 37°C and
pelleted at 1000 rpm, and the pellet was resuspended in BaF3 media
minus IL-3 containing 5 μg/ml heparan sulfate and 16 nM FGF10
for 7.5 minutes. After the incubation period, cells were centrifuged at
1000 rpm for 5 minutes, the supernatant discarded, and the cells re-
suspended in 200 μl of lysis buffer. The cell lysates were processed
and subjected to SDS-PAGE as described above.
Structural Modeling
Binding of dovitinib to FGFR2 kinase was modeled by superimpos-
ing the structure of the A-loop phosphorylated activated WT FGFR2
kinase domain (PDB ID: 2PVF) [36] onto the structure of the CHK-1
kinase domain in complex with the inhibitor 4-(aminoalkylamino)-
3-benzimidazole-quinolinones complex structure (PDB ID: 2GDO)
[37]. Similarly, binding of ponatinib to FGFR2 kinase was modeled
by superimposing the structure of the A-loop phosphorylated activated
WT FGFR2 kinase domain (PDB ID: 2PVF) [36] onto the structure
of the ABL kinase in complex with ponatinib (PDB ID: 3OY3) [38].
Modeling of the pathogenic mutations was performed and analyzed
using O [39]. Atomic superimpositions were performed using program
lsqkab [40] in CCP4 Suite [41] and structural representations were
prepared using PyMol [42].
Protein Expression and Purification
The cDNA fragment encoding residues P459 to E769 of human
FGFR2c (Accession code: NP_075259) was amplified by polymerase
chain reaction and subcloned into pET bacterial expression vector
with an NH2 terminal 6× His tag to aid in protein purification. Point
mutations (M536I, M538I, I548V, N550H, N550K, N550S, V565I,
E566G, L618M, and K660E) were introduced using QuikChange
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The bacterial
strain BL21 (DE3) cells were transformed with the expression constructs,
and kinase expression was induced with 1 mM isopropyl-L-thio-BD-
galactopyranoside overnight at the appropriate temperature. The cells
were lysed, and the soluble kinase proteins were purified according to
the published protocol [36]. N-terminally His-tagged substrate peptide
consisting of residues L762 to T822 of FGFR2 was expressed and puri-
fied similar to the kinase domain. The substrate peptide corresponds
to the C-terminal tail of FGFR2 and contains five authentic tyrosine
phosphorylation sites (Y770, Y780, Y784, Y806, and Y813).
Kinase Assay
WT and mutated FGFR2 kinases were mixed with reaction solutions
containing ATP, MgCl2, and the substrate peptide. The final concen-
trations of the reaction mix are 0.5 mg/ml kinase, 2.17 mg/ml substrate,
10 mM ATP, and 20 mM MgCl2. The reactions were quenched at
different time points by adding 100 mM EDTA. The progress of the
substrate phosphorylation was followed by native PAGE, and tyrosine
phosphorylation content of the substrate peptide was quantified by
time-resolved matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry using a Bruker Autoflex mass
spectrometer operated in linear mode according to the published pro-
tocol by comparing signals from phosphorylated and the cognate non-
phosphorylated peptides [43].
In Vitro Kinase Inhibition Assay
WT FGFR2 kinase and the N550H and V565I mutants were incu-
bated for 5minutes with reaction solutions containing ATP,MgCl2, and
increasing concentrations of either dovitinib or ponatinib. The final
concentrations of kinase, ATP, and MgCl2 were 90 μM, 5.33 mM,
and 10.66 mM, respectively. The molar ratios of kinase/inhibitor in
the reaction mix were 1:0, 1:0.2, 1:0.5, 1:1, 1:2, 1:5, or 1:10. The re-
actions were quenched by adding EDTA to a final concentration of
69.6 mM, and the progress of the kinase autophosphorylation/inhibition
was monitored by native PAGE.
Results
BaF3 Screen for Dovitinib-Resistant FGFR2 Mutations
BaF3 cells stably expressing the “b” splice isoform of FGFR2
(FGFR2b, NM_022970) were treated with 100, 200, and 300 nM
dovitinib corresponding to concentrations that are 5, 10, and 15 times
the IC50 value of dovitinib in this cell line. In the presence of 100 nM
dovitinib, 73 of 384 wells grew out, corresponding to a resistant clone
frequency of 0.76 per million cells. Nineteen of 384 wells and 9 of
384 wells grew out in the 200 and 300 nM dovitinib-treated groups,
respectively, resulting in a resistant clone frequency of 0.20 and
0.09 per million cells. Sequencing of the intracellular domain of
FGFR2 from 63 of the dovitinib-resistant BaF3.FGFR2 clones led
to the identification of mutations in 26 resistant clones (41%). The
mutation frequency increased with dovitinib concentration, with 7 of
35 (20%), 13 of 19 (68%), and 6 of 9 (67%) resistant clones contain-
ing an FGFR2 mutation for clones selected at 100, 200, and 300 nM,
respectively (Table W1).
Eleven different FGFR2 mutations, affecting nine amino acids,
were detected (Figure 1A). Ten mutations map into the kinase domain
(M536I, M538I, I548V, N550H/K/S, V565I, E566G, L618M, and
E719G), whereas the Y770fsX14 localizes to the C-terminal tail past
the kinase domain (Figure 1A). The most commonly mutated codon
was N550, with mutations accounting for 73% (19 of 26) of FGFR2
mutations. One resistant clone harbored two mutations, N550H and
E719G. Mutation at the gatekeeper residue (V565I) was identified in
one clone.
We also performed parallel dovitinib resistance screens using BaF3
cells expressing either of the FGFR2-activating mutations, S252W
or N550K. The S252W mutation is the most common FGFR2 muta-
tion seen in endometrial tumors and maps to the extracellular ligand-
binding region of FGFR2. Structural and biochemical studies have
shown that this mutation results in ligand-dependent receptor activa-
tion by introducing additional contacts between FGFR and FGF ligand
[44], and as such, we did not expect a different pattern of resistance
mutations. N550K is the second most common FGFR2 mutation
identified in endometrioid EC [45] and we show herein that this muta-
tion activates the kinase. BaF3 cells expressing S252W mutant FGFR2
show similar dovitinib sensitivity to BaF3 cells expressing WT FGFR2
(Figure W1) and were thus treated in a similar manner with 100, 200,
or 300 nM dovitinib. Resistant clones grew out in 51 of 384 wells
and the FGFR2 kinase domain was sequenced in 35 resistant clones
that grew out at the two highest dovitinib concentrations. FGFR2
mutations were identified in four clones affecting three amino acids:
N550T, E566A (two independent clones), and K642N. Although
we observed a reduced mutation rate in the resistant BaF3.FGFR2
S252W BaF3 clones, the presence of the S252W mutation did not
dramatically alter the spectrum of dovitinib-resistant mutations iden-
tified, as two of these codons (N550, E566) were also mutated in
the WT FGFR2 BaF3 screen. Moreover, all three mutations were
confirmed to confer resistance to dovitinib when expressed in con-
junction with the activating S252W mutation in proliferation assays
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(Figure W1). For the N550K resistance screen, BaF3 cells expressing
N550K mutant FGFR2 were treated with 2, 4, or 6 μM dovitinib,
corresponding to 5, 10, and 15 times the IC50, because, as noted above,
N550K already imparts significant resistance to dovitinib in isolation.
No resistant clones were isolated after dovitinib treatment in the
N550K resistance screen.
Reintroduction of the Mutations Confirmed the Identified
Mutations Induce Dovitinib Resistance
To confirm that the mutations identified in the BaF3 screen were
sufficient to confer dovitinib resistance, independent BaF3 cell lines
stably expressing FGFR2 harboring the putative drug-resistant muta-
tions identified in the initial BaF3 screen were generated (Figure 1B).
As the Y770fsX14 C-terminal deletion mapped away from the ATP-
binding site and could not be identified with the C-terminal anti-
body we used, this mutation was not assessed. The sensitivity of these
stable cell lines to dovitinib was then measured by assessing cell via-
bility at increasing dovitinib concentrations (Figure 1C ). As the acti-
vating N550K mutation was identified in the resistance screen, we
also assessed the sensitivity of the other major activating mutation
seen in patients, K660E. All mutations with the exception of
E719G led to drug resistance as manifested by 2.11 to 15.04-fold
increases in IC50 value. The N550K, V565I, K660E, and E566G
mutations imparted the greatest magnitude of resistance (Figure 1C ).
Dovitinib sensitivity of BaF3 cells expressing the E719G mutant
FGFR2 was not significantly different than that of those expressing
WT FGFR2. The clone where the E719G mutation was identified
also harbored an N550H mutation in FGFR2, so presumably the
latter N550H mutation conveyed resistance in this clone and the
E719G mutation represents a passenger mutation.
Dovitinib-resistant Mutations at N550 and E566 Disrupt
the Molecular Brake to Activate the FGFR2 Kinase
To understand the molecular mechanisms by which these mutations
confer resistance to dovitinib, a structural model of FGFR2 kinase
bound to dovitinib was created by superimposing the structure of
the A-loop phosphorylated activated WT FGFR2 kinase domain
(PDB ID: 2PVF) [36] onto the structure of the CHK-1 kinase domain
in complex with the inhibitor 4-(aminoalkylamino)-3-benzimidazole-
quinolinones complex structure (PDB ID: 2GDO) [37]. Structural
Figure 1. Identified FGFR2 mutations confer dovitinib resistance in stable BaF3.FGFR2 cells. (A) The ribbon diagram of the A-loop phos-
phorylated activated WT FGFR2 kinase structure (PDB ID: 2PVF) [36] showing the locations of the drug-resistant mutations. The A-loop
and kinase hinge are colored light purple and light orange, respectively. The drug-resistant mutations are rendered as ball and stick. The
AMP-PCP (the ATP analog) is shown in both ball-and-stick representation and a semitransparent surface. (B) Western blot analysis of
stable BaF3 cells expressing WT or mutant FGFR2 using an anti-FGFR2 antibody (BEK-C17) or anti-tubulin antibody as loading control.
(C) Stable BaF3-FGFR2 cells were seeded in 96-well plates in media containing 5 μg/ml heparan sulfate and 1 nM FGF10, and dovitinib
was added in concentrations ranging from 3 nM to 10 μM. The cells were incubated at 37°C for 72 hours and proliferation was measured
using the ViaLight proliferation kit and the IC50 was calculated using GraphPad Prism.
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analysis shows that the V565I gatekeeper mutation could confer
drug resistance by sterically hindering access of the drug into the
hydrophobic rear corner of the ATP-binding cleft of the kinase (Fig-
ure 2, A and B). In contrast, the remaining mutations are unlikely
to cause drug resistance by sterically interfering with drug binding.
Instead, these mutations appear to impart drug resistance by stabilizing
the active conformation of the FGFR2 kinase. Specifically, several of
the dovitinib-resistant mutations identified in the original and FGFR2
S252W screen (N550H/K/S/T, E566G/A, K642N) target the triad
of residues (N550, E566, and K642) that form an autoinhibitory
network of hydrogen bonds, termed the molecular brake, at the
kinase hinge region. This molecular brake restricts the motion of the
kinase into the active state [36]. Mutation of these residues have been
shown to disengage this brake, permitting the kinase to more readily
adopt the active conformation (Figure 2, C and D) [36]. These data
suggest that the N550H/K/S/T, E566G/A, and K642N dovitinib-
resistant mutations favor the active conformation of the kinase (Fig-
ure 2, E and F ), implying that dovitinib does not act on the active
kinase conformation.
Several of the dovitinib-resistant mutations, namely, M536I, M538I,
I548V, and L618M, appear to stabilize the active kinase conformation
by strengthening the hydrophobic spine of the FGFR2 kinase (Fig-
ure 2G). Furthermore, the gatekeeper residue is positioned at the top
corner of the hydrophobic spine and its mutation to bulkier hydro-
phobic residues has been also proposed to activate the kinase through
fortifying the hydrophobic spine. Together, these data suggest that
dovitinib-resistant mutations act by stabilizing the active kinase con-
formation either through disengaging the molecular brake or strength-
ening the hydrophobic spine. The V565I gatekeeper mutation can
additionally confer drug resistance through steric hindrance.
Dovitinib-resistant Mutations Elevate the Intrinsic Kinase
Activity of FGFR2
To test our structural prediction that the dovitinib-resistant muta-
tions confer resistance by stabilizing the active conformation of the
kinase, we decided to study the effect of the drug-resistant mutations
on the intrinsic kinase activity of FGFR2 kinase. Recombinant WT
and mutated kinase domains harboring the drug-resistant mutations
Figure 2. The molecular mechanisms by which mutations confer resistance to dovitinib. (A and B) Gatekeeper V565I mutation confers re-
sistance to dovitinib through steric hindrance. Binding of dovitinib [in yellow, partial, taken from the CHK-1 and inhibitor 4-(aminoalkylamino)-
3-benzimidazole-quinolinones complex structure, PDB ID: 2GDO] [37] is modeled onto the A-loop phosphorylated activated WT FGFR2
kinase structure (PDB ID: 2PVF) [36]. Hydrogen bonds between the kinase and dovitinib are colored yellow. Themolecular surface of dovitinib
is shown to emphasize the steric clash with the mutated I565. (C–F) Mutations at N550 and E566 confer dovitinib resistance by activating
the kinase through disengagement of the molecular brake. The molecular brake is engaged at the kinase hinge region in the unphosphory-
lated unactivated WT FGFR2 kinase (C; PDB ID: 2PSQ) [36] and is disengaged by A-loop tyrosine phosphorylation (D; PDB ID: 2PVF) [36] or
by mutations at N550 (E; PDB ID: 2PWL) [36] and E566 (F; PDB ID: 2PY3) [36]. (G) Some mutations confer dovitinib resistance by activating
the kinase through strengthening the hydrophobic spine of the FGFR2 kinase. The hydrophobic spine is shown as a semitransparent sur-
face. Residues comprising the hydrophobic spine are rendered as sticks. The drug-resistantmutations targeting residues V565, M536, M538,
I548, and L618 are colored and labeled green, and the others are labeled white.
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were expressed and purified to homogeneity, and their substrate phos-
phorylation activities were compared using native PAGE coupled with
time-resolved mass spectrometry. Briefly, WT or drug-resistant mutant
FGFR2 kinases were incubated with peptide substrate in the presence
of ATP and MgCl2. The C-terminal tail of the FGFR2 kinase, which
contains five authentic phosphorylation sites, served as the substrate.
Phosphorylation reactions were quenched at different time points with
the addition of EDTA. The formation of phosphorylated species was
monitored by native PAGE and analyzed by mass spectrometry and the
percentage of at least one site phosphorylation on the substrate was
quantitated using the peak intensity data generated by mass spectrom-
etry (Figures 3A and W2). Compared to WT kinase, the drug-resistant
mutant FGFR2 kinases exhibited increased ability to phosphorylate the
substrate, demonstrating that the dovitinib-resistant mutations elevate
the intrinsic activity of the enzyme.
Dovitinib-resistant Mutations Result in Ligand-Dependent
Receptor Activation In Vitro
To validate our in vitro data, we next tested the ability of the drug-
resistant mutations to elevate the kinase activity of full-length receptor
by measuring ligand-independent and ligand-dependent proliferation
of the BaF3 cell lines expressing the drug-resistant FGFR2b mutants.
None of the dovitinib-resistant mutations was sufficient to significantly
drive FGF-independent cell survival and proliferation (Figure W3A).
Figure 3. Dovitinib-resistant mutations increase the intrinsic kinase activity of FGFR2. (A) The substrate phosphorylation activities of WT and
mutated FGFR2 kinase domain harboring the drug-resistantmutationswere compared using native PAGE (panel I) coupledwith time-resolved
mass spectrometry (MS; panels II and III). For accuracy, only the early time point (30- and 60-second) MS data, which are in the linear phase of
the kinase assay, were processed. The percentage of at least one site phosphorylation on the substrate (panel III) was estimated using the
peak intensity data generated by mass spectrometry. (B) Stable BaF3.FGFR2 cells were seeded at 10,000 cells/well in 96-well plates in media
containing 5 μg/ml heparan sulfate and 1 nM FGF10. The cells were incubated at 37°C for 72 hours and proliferation was measured using
the ViaLight proliferation kit. The increase in proliferation compared to FGFR2 WT cells is presented. (C) Stable BaF3 cells expressing WT
or mutant FGFR2 were stimulated for 7.5 minutes with media containing 5 μg/ml heparan sulfate and 16 nM FGF10. After the stimulation
period, the cells were lysed in lysis buffer containing phosphatase inhibitors, and 150 μg of total protein was separated on an SDS-PAGE,
transferred to a nitrocellulose membrane, and probed with an anti–pan-phospho-FGFR, anti-FGFR2 (BEK-C17), and anti-tubulin antibodies.
The ratio of phospho to total FGFR2 was calculated by densitometry using Odyssey 3.0 software.
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These data may seem conflicting with the in vitro data showing these
mutations have constitutive activity; however, comparative data sug-
gest that FGFR2 is not able to drive IL-3–independent BaF3 prolifera-
tion in the same way as FGFR1, perhaps reflecting its reduced overall
kinase activity. Specifically, BaF3 cells expressing FGFR1c N546K
demonstrate significant proliferation compared to WT in the absence
of ligand in contrast to the homologous N550K mutation in FGFR2c
that does not (Figure W3B). Nevertheless, in the presence of FGF10
(a well-known cognate ligand of FGFR2b), BaF3 cell lines expressing
each of the dovitinib-resistant mutants displayed increased prolifera-
tion compared to cells expressing WT FGFR2 (Figure 3B), supporting
the in vitro findings that the dovitinib-resistant mutations increase
the tyrosine kinase activity of full-length FGFR2b.
To further corroborate our findings, cell lines expressing drug-
resistant FGFR2b mutants were incubated with heparan sulfate and
FGF10 for 7.5 minutes, and the receptor phosphorylation was assessed
by Western blot analysis using a phospho-FGFR antibody. Densito-
metric analysis of biologic replicate experiments shows that the drug-
resistant FGFR2 mutants exhibited a five-fold to six-fold increase in
autophosphorylation compared to the WT FGFR2 (Figure 3C ). No
increase in BaF3 proliferation or receptor phosphorylation in response
to FGF10 was seen in the BaF3 cells transduced with FGFR2 K660E,
although this mutated receptor shows strong constitutive activity in
the absence of ligand (Figure W3B). This is consistent with mislocali-
zation of this activating mutant to the endoplasmic reticulum (ER)/
Golgi, similar to what has been reported previously for the K650E
mutation in FGFR3 [46,47]. Taken together with the in vitro kinase
assay data, these cell-based data demonstrate that the dovitinib-resistant
mutations increase the tyrosine kinase activity of FGFR2.
Mutations Cause Cross-Resistance to PD173074 but Not
to Ponatinib
To examine whether the identified dovitinib-resistant FGFR2
mutations can also confer resistance to other FGFR inhibitors, ligand-
induced proliferation of BaF3 cells expressing the drug-resistant FGFR2
was measured in the presence of PD173074 and ponatinib. As shown
in Figure 4A, the dovitinib-resistant mutations also imparted resistance
to PD173074. As with dovitinib, the N550K molecular brake region
mutation and the V565I gatekeeper mutation also caused greatest
resistance toward PD173074. Interestingly, the N550K mutation
provided considerably more resistance than N550H and N550S, per-
haps indicating that the conformation of N550K provides resistance
through another mechanism, in addition to loss of the molecular brake.
In contrast, ponatinib effectively inhibited all the dovitinib-resistant
FGFR2 mutants with the exception of the V565I gatekeeper mutant
(Figure 4B).
To further explore the differential sensitivity of ponatinib to the
dovitinib-resistant mutations, BaF3 cell lines expressing WT FGFR2b
or N550K and V565I drug-resistant FGFR2b mutants were incubated
with dovitinib or ponatinib followed by FGF10 ligand stimulation
and the phosphorylation of FGFR2 was examined. Treatment with
dovitinib reduced receptor phosphorylation in BaF3.FGFR2 WT cells
to ∼50% at a concentration of 52.1 nM (Figure 5, A and B). In
contrast, the concentration of dovitinib required to reduce receptor
phosphorylation to ∼50% in BaF3.FGFR2 N550K and BaF3.FGFR2
V565I cells was 794 and 954 nM, respectively. Ponatinib inhibited
phosphorylation of WT FGFR2b with an IC50 of 30.73 nM that is
comparable to that of dovitinib. In stark contrast to dovitinib, ponatinib
was highly effective in inhibiting the N550K FGFR2 mutant (IC50
of 5.72 nM), demonstrating the sensitivity of this FGFR2 mutant to
ponatinib. Notably, the V565I gatekeeper mutant was still refractory
to inhibition by ponatinib (IC50 of 661 nM), emphasizing the potency
of this mutation to confer resistance to all three FGFR inhibitors.
EC Cell Lines Expressing Various FGFR2 Mutations
(N550K, S252W, and C383R) Demonstrate Both
Sensitivity and Intrinsic Resistance to FGFR Inhibition
Our laboratory and others have reported that the AN3CA and
MFE296 cell lines, which carry the N550K FGFR2 mutation, are sen-
sitive to FGFR inhibition with PD174074 [48,49]. To better gauge
the relevance of the N550K mutation in resistance to FGFR inhibi-
tion in the correct cellular context, we identified four additional cell
lines with mutations in FGFR2 (Gordon Mills, personal communi-
cation). We hypothesized that a comparison of the mutant FGFR2
cell lines would show that all cell lines would be equally sensitive to
Figure 4. Dovitinib resistance mutations are similarly resistant to
PD173074 but are almost all sensitive to ponatinib. (A) Stable
BaF3-FGFR2 cells were seeded in 96-well plates in media contain-
ing 5 μg/ml heparan sulfate and 1 nM FGF10, and PD173074 was
added in concentrations ranging from 3 nM to 10 μM. The cells
were incubated at 37°C for 72 hours and proliferation was mea-
sured using the ViaLight proliferation kit and the IC50 was calculated
using Prism (GraphPad Software). (B) Cells were treated as in A, but
0.1 nM to 1 μM ponatinib was added to each stable cell line.
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Figure 5. Change in FGFR2 phosphorylation in response to treatment with dovitinib and ponatinib. (A) Stable BaF3.FGFR2 cells were
pretreated in IL-3–free BaF3 media for 90 minutes at 37°C. After the 90-minute incubation period, the media were removed and the
cells were incubated for 7.5 minutes at 37°C with media containing 5 μg/ml heparan sulfate and 16 nM FGF10. Cells were lysed in lysis
buffer containing phosphatase inhibitors and 150 μg of total protein was separated on an SDS-PAGE, transferred to a nitrocellulose
membrane, and probed using an anti–pan-phospho-FGFR, anti-FGFR2 (BEK-C17), and anti-tubulin antibodies. (B) Densitometry analy-
sis of the change in phosphorylation due to pretreatment with dovitinib and ponatinib. The ratio of phospho to total FGFR2 was cal-
culated by densitometry using Odyssey 3.0 software and the concentration required to decrease the phosphorylation to 50% compared
to WT.
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ponatinib but that the N550K lines could show relative resistance to
PD173074 and dovitinib (compared to cell lines carrying S252W
and C383R FGFR2 mutations).
Sensitivity across the panel was in the order ponatinib (most sen-
sitive), then dovitinib, then PD173074 (least sensitive). Ponatinib
was more potent than the other FGFR inhibitors in both the FGFR2
mutant and FGFR2 WT cell lines (e.g., Ishikawa), suggesting that its
increased potency was not only due to its ability to bind the active
FGFR2 but also due to its multi-kinase nature. We should note that
the IC50 values we report are higher than those that we and others
have reported previously for several cell lines. However, in this report,
we directly measured cell proliferation with a nucleic acid–based kit
rather than a metabolic-based assay [48,50] or one based on cellular
protein content [49]. Within the FGFR2mutant cell lines, three of seven
showed marked resistance to PD173074 (IC50 > 4 μM) including EI,
EJ, and EN1078D. With the exception of EN1078D treated with
dovitinib, these three FGFR2mutant cell lines also showed relative re-
sistance to dovitinib and ponatinib when compared to the average
IC50 of the three most sensitive cell lines versus that of the three
FGFR2wild-type cell lines (Table 1). As the same cell lines showed
similar relative resistance to PD173074, dovitinib, and ponatinib, it
suggests that these cell lines have intrinsic resistance to FGFR inhibi-
tion that is not overcome by an inhibitor that is capable of binding to
the active conformation of the kinase.
Stable Expression of N550K Mutant FGFR2 in Inhibitor
Sensitive JHUEM-2 Cells Confers Resistance to PD173074
As those EC cell lines carrying the N550K mutation had a diverse
response to FGFR inhibition (presumably reflecting the acquisition of
additional genetic/epigenetic changes), we sought an alternative ap-
proach to confirm whether FGFR2N550K is a true resistance mutation.
We stably transfected the sensitive JHUEM-2 cell line (FGFR2C383R)
with FGFR2N550K. JHUEM-2 cells stably expressing an empty vec-
tor control, WT FGFR2, and an extracellular domain activating
FGFR2 mutant (Y376C) were also created. We then measured the cell
viability of these lines in response to FGFR inhibition with dovitinib,
PD173074, and ponatinib. Although expression of FGFR2N550K did
not affect the sensitivity of JHUEM-2 cells to dovitinib and ponatinib,
it did, however, cause an about five-fold increase in the IC50 to
PD173074 (Figure 7A). As demonstrated in Figure 7B, all three WT
and mutant FGFR2-transfected cell lines express higher levels of
FGFR2 than the empty vector control line. Indeed, the FGFR2N550K
expressing cells expressed less FGFR2 than the FGFR2Y376C cell line,
and yet only the FGFR2N550K cells showed increased resistance to
PD173074. While N550K did not confer resistance to dovitinib and
ponatinib when expressed at low levels in JHUEM cells, we were able
to confirm that N550H imparts resistance to dovitinib using in vitro
kinase assays (Figure 7C ). Similar to the N550H/K-expressing BaF3
cells, in vitro kinase assays showed that N550H was more sensitive to
ponatinib than dovitinib. Specifically, dovitinib and ponatinib could
inhibit the kinase activity of WT FGFR2 when mixed at a kinase/
inhibitor molar ratio of 1:2. Ponatinib could inhibit N550H at a simi-
lar molar ratio, whereas dovitinib could not provide the same inhibi-
tion even at a molar ratio of 1:10. The kinase activity of the V565I
mutant was resistant to both dovitinib and ponatinib even when
mixed at a molar ratio of 1:10. These results confirm the BaF3 data
showing that ponatinib is more effective than dovitinib at inhibiting
FGFR2N550K and that the V565I gatekeeper mutant is resistant to
both dovitinib and ponatinib. Taken together, this confirms our BaF3
data that FGFR2N550K is indeed a true resistance mutation.
Discussion
This study provides the first discovery of TKI-resistant mutations in
FGFR2, an important drug target in EC. These mutations include
M536I, M538I, I548V, N550H/K/S/T, V565I, E566G/A, L618M,
and K642N. Given the identification of N550K, we also investigated
the clinically relevant activating mutation, K660E, and showed that it
was associated with resistance to dovitinib and PD173074. Identifica-
tion of the V565I mutation in our screen reiterates mutation of the
gatekeeper residue as a general mechanism of acquired resistance to
TKIs. Importantly, our structural and biochemical data show that these
mutations stabilize the active conformation of FGFR2 kinase mani-
festing in increased intrinsic activity of the drug-resistant FGFR2K
mutants. Although several resistance mutations were not functionally
tested (N550T, E566A, and K642N), data from the remaining muta-
tions indicate that seven of the identified resistance mutations, namely,
N550H/K/S/T, E566G/A, and K642N, drive the enzyme into the
active state by disengaging the autoinhibitory molecular brake at the
kinase hinge region. The remaining five mutations, namely, M536I,
M538I, I548V, V565I, and L618M, stabilize the kinase active confor-
mation by strengthening the hydrophobic spine, a network of hydro-
phobic packing interactions between the N- and C-lobe of the kinase
that characterizes the active conformation of the kinase. It has been
suggested that dovitinib may inhibit both the active and inactive
forms of VEGFR [4]. However, our findings indicate that dovitinib
and PD173074 preferentially bind the inactive form of the FGFR2
kinase. In contrast, ponatinib effectively inhibited all of the FGFR2-
activating mutations except the V565I gatekeeper mutation, suggesting
that ponatinib is capable of targeting both the inactive and the
Table 1. Sensitivity of Endometrial Cancer Cell Lines to PD173074, Dovitinib and Ponatinib.
EC Cell Line FGFR2 Status Dovitinib IC50 (nM) PD173074 IC50 (nM) Ponatinib IC50 (nM)
AN3CA FGFR2N550K 449 ± 114 761 ± 130 58 ± 13
MFE296 FGFR2N550K 614 ± 18 821 ± 71 104 ± 29
EJ FGFR2N550K 2374 ± 789 >10,000 949 ± 241
EN1078D FGFR2N550K 770 ± 174 4475 ± 258 614 ± 18
MFE280 FGFR2S252W 1503 ± 381 821 ± 71 230 ± 52
EI FGFR2S252W 1268 ± 146 5161 ± 149 729 ± 21
JHUEM-2 FGFR2C383R 558 ± 111 183 ± 41 145 ± 33
HEC1A WT 3572 ± 409 >10,000 1519 ± 260
Ishikawa WT 1850 ± 662 8749 ± 1251 669 ± 222
KLE WT 4751 ± 1933 >10,000 1167 ± 167
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active conformations of the kinase. Modeling studies suggest that the
gatekeeper mutation, in addition to strengthening the hydrophobic
spine, may also create a steric conflict for drug binding, explaining the
exceptional resistance of this mutation to ponatinib (Figure 6).
Amino acids corresponding to all the dovitinib-resistant mutations
identified in FGFR2 are conserved among the other three members of
the FGFR family. Therefore, it is likely that the corresponding muta-
tions in other FGFR family members could impart dovitinib resistance
in tumors that are dependent on these FGFRs. All three constituents
of the molecular brake (N550, E566, and K642) and several residues
of the hydrophobic spine in FGFR2b are also conserved in VEGFR1,
VEGFR2, PDGFRA, PDGFRB, c-KIT, and FLT3. Indeed, mutations
at the homologous residue to FGFR2 (N550) in FLT3 (N676) have
been linked to resistance to the kinase inhibitor PKC412, including
clinical resistance in a patient with acute myeloid leukemia [28,51].
Conversely, N659 in PDGFRA (homologous to N550 in FGFR2) is
mutated in a subset of GIST tumors, but this mutation does not result
in imatinib resistance in vitro [33].
In addition to being the most commonly mutated codon identi-
fied in our resistance screen, N550 is also the second most common
amino acid of FGFR2 altered in endometrioid EC [45,52]. As such,
cancer patients carrying activating mutations at N550 may be resis-
tant to the anti-FGFR activity of dovitinib, whereas patients harbor-
ing FGFR2 mutations outside the kinase domain would be expected
to achieve more clinically significant responses. Preliminary findings
from a phase I/II pharmacodynamic study indicate that oral adminis-
tration of dovitinib at 400 mg/day results in plasma Cmax drug levels
of 119 to 382 ng/ml (247–792 nM) [15]. With a half-life of approxi-
mately 12 hours, dovitinib plasma Cmin levels would be expected
to be approximately 25% those of the Cmax levels (in the order of
62–198 nM). On the basis of our in vitro data, effective inhibition
of N550K, E566G, K660E, and V565I would not be expected with
these plasma concentrations. Thus, we propose that patients present-
ing with N550 and K660 mutations potentially be treated with higher
doses of dovitinib and for their plasma concentrations to be analyzed
and correlated with clinical response. It should be noted, however,
that dovitinib should still exert anti-angiogenic activity in patients with
the N550K mutation owing to its additional inhibition of VEGFR
and PDGFR [15] and the established efficacy of bevacizumab in this
patient population [53]. That being said, we would predict fewer
partial and complete responses in patients carrying kinase domain
mutations due to its reduced anti-tumor efficacy. All mutations except
V565I (which may possibly arise in the context of ponatinib-selective
pressure) are effectively inhibited at achievable plasma levels of ponatinib,
and as such, a multi-institutional phase II trial of ponatinib in FGFR2
mutation–positive EC patients is currently in development.
The prevalence of drug-resistant mutations affecting N550 was
somewhat surprising, considering the fact that we, and others, have
previously shown that EC cell lines with FGFR2b N550K mutation
are sensitive to PD173074 [48,49]. This inconsistency is an important
one as our BaF3 resistance screen results may not be readily translated
into the clinic in EC patients treated with dovitinib. To better gauge
the relevance of the N550K resistance mutation in EC cell lines, we ran
all three FGFR inhibitors in this study across a number of N550K
mutant, non–N550K mutant, and FGFR2 WT cell lines. While we
confirmed the JHUEM-2 cell line as an additional sensitive cell line,
the EJ, EI, and, to a lesser extent, EN1078D cell lines showed resistance
to the panel of kinase inhibitors. Of these EJ and EN1078D carried an
N550K mutation and EI carried an S252Wmutation. Previous data in-
dicate that the MFE319 cell line carrying an S252W mutation is also
resistant to FGFR inhibition [54]. Therefore, only four of eight (50%)
of the EC cell lines with known activating mutations show sensitivity
to FGFR inhibition, contrasting with our original findings where two
of two cell lines showed sensitivity. As sensitivity/resistance does not
correlate with any specific mutation, sensitivity to FGFR inhibition
appears to be more complex than simply which FGFR2 mutation is
present. Perhaps intuitively, sensitivity is greater for those FGFR in-
hibitors, like dovitinib and ponatinib, with multiple kinase targets. Im-
portantly, our cell line findings highlight the importance of intrinsic
resistance to FGFR inhibition in EC, such that additional assessment
of biomarkers of sensitivity and resistance may be required before the
clinical success of FGFR inhibition is observed in patients.
To better approach the question as to whether FGFR2N550K is a true
resistance mutation, we stably transfected the sensitive non–N550K
Figure 6. The V565I gatekeeper FGFR2 kinase mutant is also refractory to inhibition by ponatinib due to steric conflicts. Ponatinib taken
from the Abl-ponatinib complex structure (PDB ID: 3OY3) [38] was modeled onto the A-loop phosphorylated activated WT FGFR2 kinase
structure (PDB ID: 2PVF) [36]. The molecular surface of ponatinib (in yellow) is shown to emphasize the steric clash with the mutated I565.
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mutant (FGFR2C383R) EC cell line JHUEM-2 with an FGFR2N550K-
expressing construct and compared its response to FGFR inhibition
with that of other JHUEM-2 lines similarly transfected with relevant
controls. Strikingly, the presence of FGFR2N550K in JHUEM-2 cells
conferred an about five-fold increase in IC50 to PD173074 in this cell
line, confirming our BaF3 screen results that FGFR2N550K is indeed a
true resistance mutation. Although there was no increase in resistance
to dovitinib in the FGFR2N550K-transfected JHUEM-2 cells, we hy-
pothesize that this is due to a combination of low levels of FGFR2N550K
combined with receptor heterodimerization and the fact that the
N550K allele provides relatively less resistance to dovitinib. Specifically,
in the BaF3 assay, N550K provides less resistance to dovitinib than
Figure 7. The N550K mutation confers resistance to PD173074, but not dovitinib or ponatinib, when expressed in FGFR inhibitor–sensitive
JHUEM-2 cells. (A) Stably transfected JHUEM-2 cells were seeded in 96-well plates 24 hours before drug addition. Dovitinib, PD173074,
and ponatinib were added in increasing concentrations from 1 nM to 10 μM. The cells were incubated at 37°C for 72 hours and prolifera-
tion was measured using the CyQUANT Cell Proliferation Assay Kit and the IC50 was calculated. (B) Western blots demonstrating FGFR2
expression levels in stably transfected JHUEM-2 lines. EV, empty vector. (C) Both dovitinib and ponatinib are potent inhibitors of the WT
FGFR2 kinase, whereas only ponatinib effectively inhibits the N550H mutant FGFR2. Due to the steric clash, neither dovitinib nor ponatinib
is capable of inhibiting the V565I “gatekeeper” mutant. The control lane 1 shows extent of phosphorylation in the absence of inhibitors.
In lanes 2 to 7, increasing concentrations of inhibitors were added into the autophosphorylation reactions to inhibit the kinase auto-
phosphorylation. The kinase/inhibitor molar ratios of lanes 2 to 7 are 1:0.2, 1:0.5, 1:1, 1:2, 1:5, and 1:10, respectively. The control lane 0
is the kinase in the absence of ATP/MgCl2.
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PD173074 (∼15× WT IC50 vs ∼250× WT IC50), but we must be
cognizant of the fact that BaF3 cells express no endogenous FGFR2
and so we are measuring the drug resistance associated with homo-
dimerization of the FGFR2N550K allele. In contrast, the JHUEM-2
cell line expresses a high level of endogenous FGFR2C383R and there
are relatively low expression levels of FGFR2N550K compared to en-
dogenous FGFR2C383R (see Figure 7). In this case, we presume that
the relative small proportion of receptor dimers carrying FGFR2N550K
on a background of high FGFR2C383R expression is sufficient to pro-
vide resistance to PD173074 but not to dovitinib. To provide addi-
tional data that FGFR2N550K provides resistance to dovitinib but not
ponatinib, additional in vitro kinase assays were performed. These
showed that while both inhibitors showed poor activity against the
gatekeeper mutation, ponatinib showed greater activity than dovitinib
against the N550H mutation. Taken together, this confirms our BaF3
data that FGFR2N550K is indeed a true resistance mutation; however,
we must await the clinical data to see to what extent this is reflected
in patients.
In conclusion, we have identified FGFR2 mutations, including
the common N550K mutation capable of conferring resistance to
dovitinib in BaF3 assays. These drug-resistant mutations increase RTK
activity by disengaging the molecular brake or by stabilizing the hydro-
phobic spine of FGFR2. Introduction of the drug-resistant FGFR2N550K
allele into the FGFR2C383R JHUEM cell line resulted in a six-fold
increase in resistance to PD173074. With the evaluation of four addi-
tional FGFR2 mutant EC cell lines and the finding that only two of
four EC cell lines with N550K mutations and one of three cell lines
with S252W mutations are sensitive to dovitinib and ponatinib, addi-
tional markers of drug sensitivity and/or resistance are required.We look
forward to the ongoing dovitinib trial in EC patients to see if patients
with heterozygous or homozygous activating kinase domain mutations
respond as well as those with mutations in other domains. If previous
experience with other kinase inhibitors can be assumed to hold true
for anti-FGFR agents, future drug design should focus on inhibiting
the active conformation of the FGFRs, as well as the development of
second-generation inhibitors targeting the gatekeeper form of FGFR2.
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Table W1. Number of Colonies Obtained in the BaF3 Screen.
Screen Concentration Cells Seeded
per Well
Wells Seeded Wells with
Outgrowth
Clones
Sequenced
Mutant Clones of
Sequenced Colonies
Mutants Occurrence Frequency among
Clones
Frequency among
Mutants
FGFR2b screen 100 nM (5 × IC50) 1 × 10
5 192 31 24 7 of 35 Parental 28 80
M538I 1 2.9 14.3
N550H 4 11.4 57.1
4 × 105 192 42 11 E566G 1 2.9 14.3
L618M 1 2.9 14.3
200 nM (10 × IC50) 1 × 10
5 192 8 8 13 of 19 Parental 6 31.6
M536I 1 5.3 7.7
I548V 1 5.3 7.7
4 × 105 192 11 11 N550H 10 52.6 76.9
V565I 1 5.3 7.7
300 nM (15 × IC50) 1 × 10
5 192 3 3 6 of 9 Parental 3 33.3
N550H 3 33.3 50
N550K 1 11.1 16.7
4 × 105 192 6 6 N550S 1 11.1 16.7
Y770IfsX14 1 11.1 16.7
FGFR2b S252W screen 100 nM (5 × IC50) 1 × 10
5 192 148 None
4 × 105 192 147
200 nM (10 × IC50) 1 × 10
5 192 29 20 3 of 20 Parental 17 85
N550T 1 5 33.3
E566A 2 10 66.7
4 × 105 192 58 0
300 nM (15 × IC50) 1 × 10
5 192 4 1 1 of 15 Parental 14 93.3
K642N 1 6.7 100
4 × 105 192 18 14
Figure W1. Sensitivity of compound FGFR2S252W dovitinib resistance
mutations to dovitinib. The IC50 values of FGFR2 WT, FGFR2
S252W
WT, and FGFR2S252W mutant (N550T, E566A, and K642N) BaF3 lines
are presented. All three kinase mutations identified conferred signifi-
cant resistance to dovitinib.
Figure W2. Dovitinib-resistant mutations increase the intrinsic kinase activity of FGFR2. The substrate phosphorylation activities of WT
and mutated FGFR2 kinase domain harboring the drug-resistant mutations were compared using native PAGE (panel I) coupled with
time-resolved mass spectrometry (panels II and III). For accuracy, only the early time point (30- and 60-second) MS data, which are in
the linear phase of the kinase assay, were processed. The percentage of at least one site phosphorylation on the substrate (panel III) was
estimated by comparing peak intensities generated by mass spectrometry of phosphorylated and nonphosphorylated substrate peptides.
Figure W3. Ligand-independent proliferation of stable BAF3-FGFR2
cells. (A) FGFR2 WT and mutants are not sufficient to drive ligand-
independent proliferation in BaF3 cells. Stable BaF3.FGFR2 cells
were seeded at 10,000 cells/well in 96-well plates in IL-3–free
media. The cells were incubated at 37°C for 72 hours and prolifer-
ation was measured using the ViaLight proliferation kit. The in-
crease in proliferation compared to FGFR2 WT cells is presented.
(B) In both the absence and presence of ligand, the homologous
N546K mutation in FGFR1c can drive significantly more BaF3 pro-
liferation than the FGFR2c N549K mutation, indicating the relative
weak strength of FGFR2 in vivo.
